You are here: Home » NEWS » These Drugs Raise Hope of Oral Treatment for Type 1 Diabetes
These Drugs Raise Hope of Oral Treatment for Type 1 Diabetes

These Drugs Raise Hope of Oral Treatment for Type 1 Diabetes

In the absence of any drugs specifically created to treat type 1 diabetes, people living with the condition manage their health with insulin injections and diet modifications. However, two drugs, Zynquista (sotogliflozin) and Forxiga (dapagliflozin), are now on a quest to be the first approved oral treatment of type 1 diabetes, with varying levels of success.

On Friday, the U.S. Food and Drug Administration (FDA) announced Zynquista would not be approved.

Zynquista is what’s known as a sodium-glucose cotransporter 1 and 2 (SGLT-1/2) inhibitor. It works by inhibiting two proteins that regulate glucose. Inhibiting one of the proteins delays the absorption of glucose in the intestine, which helps control blood sugar levels after meals. Inhibiting the second protein prevents re-absorption of glucose in the kidney. This results in the loss of glucose through the urine, rather than in the blood.

Zynquista wouldn’t replace insulin but would be used alongside it. Studies found that taking sotagliflozan tablets helped people have fewer severe hypoglycemia episodes, require lower insulin doses and reach their target A1C level. An elevated risk of diabetic ketoacidosis was also discovered, as well as possible side effects including vaginal yeast infection and diarrhea.

Related:​ Diabetes Download: How Do I Know If I’m Taking the Right Amount of Basal Insulin?

Though Zynquista was not approved for use in the U.S., it is still under review in Europe, and according to the nonprofit Beyond Type 1, it is more likely to be approved there than in the U.S. since reviews in Europe have been more positive.

Forxiga (dapagliflozin) was approved to treat type 1 diabetes in Europe on Monday. Known as Farxiga in the U.S., the drug is an SLGT-2 inhibitor already used to treat type 2 diabetes. The FDA is currently reviewing Farxiga as a type 1 diabetes drug.

Like Zynquista, Farxiga does not replace insulin but is used alongside it. Studies showed it can help contribute to lower HbA1c levels, weight loss, and lower daily insulin requirements. The drug has been approved specifically for people with a body mass index (BMI) over 27 who aren’t meeting their blood sugar targets on insulin alone.

read more

Please Submit News, Articles, Enquiries And More To :
Please follow and like us:



Leave a Reply

Your email address will not be published. Required fields are marked *


Scroll To Top

Enjoy this blog? Please spread the word :)

Follow by Email